Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

CD8+T-bet+ cells as a predominant biomarker for inclusion body myositis.

Dzangué-Tchoupou G, Mariampillai K, Bolko L, Amelin D, Mauhin W, Corneau A, Blanc C, Allenbach Y, Benveniste O.

Autoimmun Rev. 2019 Feb 28. pii: S1568-9972(19)30029-1. doi: 10.1016/j.autrev.2019.02.003. [Epub ahead of print] Review.

PMID:
30825520
2.

Responsiveness to Change of 5-point MRC scale, Endurance and Functional Evaluation for Assessing Myositis in Daily Clinical Practice.

Landon-Cardinal O, Devilliers H, Chavarot N, Mariampillai K, Rigolet A, Hervier B, Allenbach Y, Benveniste O.

J Neuromuscul Dis. 2019;6(1):99-107. doi: 10.3233/JND-180358.

PMID:
30714969
3.

Diagnostic potential of sarcoplasmic MxA expression in subsets of dermatomyositis.

Uruha A, Allenbach Y, Charuel JL, Musset L, Aussy A, Boyer O, Mariampillai K, Landon-Cardinal O, Rasmussen C, Bolko L, Maisonobe T, Leonard-Louis S, Suzuki S, Nishino I, Stenzel W, Benveniste O.

Neuropathol Appl Neurobiol. 2018 Sep 28. doi: 10.1111/nan.12519. [Epub ahead of print]

PMID:
30267437
4.

Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies.

Mariampillai K, Granger B, Amelin D, Guiguet M, Hachulla E, Maurier F, Meyer A, Tohmé A, Charuel JL, Musset L, Allenbach Y, Benveniste O.

JAMA Neurol. 2018 Dec 1;75(12):1528-1537. doi: 10.1001/jamaneurol.2018.2598.

PMID:
30208379
5.

Necrosis in anti-SRP+ and anti-HMGCR+myopathies: Role of autoantibodies and complement.

Allenbach Y, Arouche-Delaperche L, Preusse C, Radbruch H, Butler-Browne G, Champtiaux N, Mariampillai K, Rigolet A, Hufnagl P, Zerbe N, Amelin D, Maisonobe T, Louis-Leonard S, Duyckaerts C, Eymard B, Goebel HH, Bergua C, Drouot L, Boyer O, Benveniste O, Stenzel W.

Neurology. 2018 Feb 6;90(6):e507-e517. doi: 10.1212/WNL.0000000000004923. Epub 2018 Jan 12.

PMID:
29330311
6.

Anti-mitochondrial antibodies are not a hallmark of severity in idiopathic inflammatory myopathies.

Mauhin W, Mariampillai K, Allenbach Y, Charuel JL, Musset L, Benveniste O.

Joint Bone Spine. 2018 May;85(3):375-376. doi: 10.1016/j.jbspin.2017.04.004. Epub 2017 Apr 20. No abstract available.

PMID:
28435082
7.

Cytosolic 5'-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis.

Lilleker JB, Rietveld A, Pye SR, Mariampillai K, Benveniste O, Peeters MT, Miller JA, Hanna MG, Machado PM, Parton MJ, Gheorghe KR, Badrising UA, Lundberg IE, Sacconi S, Herbert MK, McHugh NJ, Lecky BR, Brierley C, Hilton-Jones D, Lamb JA, Roberts ME, Cooper RG, Saris CG, Pruijn GJ, Chinoy H, van Engelen BG; all UKMYONET contributors.

Ann Rheum Dis. 2017 May;76(5):862-868. doi: 10.1136/annrheumdis-2016-210282. Epub 2017 Jan 25.

8.

Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients.

Masat E, Laforêt P, De Antonio M, Corre G, Perniconi B, Taouagh N, Mariampillai K, Amelin D, Mauhin W, Hogrel JY, Caillaud C, Ronzitti G, Puzzo F, Kuranda K, Colella P, Mallone R, Benveniste O, Mingozzi F; French Pompe Registry Study Group.

Sci Rep. 2016 Nov 4;6:36182. doi: 10.1038/srep36182.

9.

Pulmonary arterial hypertension in idiopathic inflammatory myopathies: Data from the French pulmonary hypertension registry and review of the literature.

Sanges S, Yelnik CM, Sitbon O, Benveniste O, Mariampillai K, Phillips-Houlbracq M, Pison C, Deligny C, Inamo J, Cottin V, Mouthon L, Launay D, Lambert M, Hatron PY, Rottat L, Humbert M, Hachulla E.

Medicine (Baltimore). 2016 Sep;95(39):e4911. doi: 10.1097/MD.0000000000004911. Review.

10.

High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody.

Allenbach Y, Keraen J, Bouvier AM, Jooste V, Champtiaux N, Hervier B, Schoindre Y, Rigolet A, Gilardin L, Musset L, Charuel JL, Boyer O, Jouen F, Drouot L, Martinet J, Stojkovic T, Eymard B, Laforêt P, Behin A, Salort-Campana E, Fain O, Meyer A, Schleinitz N, Mariampillai K, Grados A, Benveniste O.

Brain. 2016 Aug;139(Pt 8):2131-5. doi: 10.1093/brain/aww054. Epub 2016 Apr 17.

PMID:
27086869
11.

Efficacy of Rituximab in Refractory Inflammatory Myopathies Associated with Anti- Synthetase Auto-Antibodies: An Open-Label, Phase II Trial.

Allenbach Y, Guiguet M, Rigolet A, Marie I, Hachulla E, Drouot L, Jouen F, Jacquot S, Mariampillai K, Musset L, Grenier P, Devilliers H, Hij A, Boyer O, Herson S, Benveniste O.

PLoS One. 2015 Nov 5;10(11):e0133702. doi: 10.1371/journal.pone.0133702. eCollection 2015.

12.

Innate and Adaptive Immune Response in Fabry Disease.

Mauhin W, Lidove O, Masat E, Mingozzi F, Mariampillai K, Ziza JM, Benveniste O.

JIMD Rep. 2015;22:1-10. doi: 10.1007/8904_2014_371. Epub 2015 Feb 18.

13.

Four-year longitudinal study of clinical and functional endpoints in sporadic inclusion body myositis: implications for therapeutic trials.

Hogrel JY, Allenbach Y, Canal A, Leroux G, Ollivier G, Mariampillai K, Servais L, Herson S, Decostre V, Benveniste O.

Neuromuscul Disord. 2014 Jul;24(7):604-10. doi: 10.1016/j.nmd.2014.04.009. Epub 2014 May 4.

PMID:
24857365
14.

Restoration of regulatory and effector T cell balance and B cell homeostasis in systemic lupus erythematosus patients through vitamin D supplementation.

Terrier B, Derian N, Schoindre Y, Chaara W, Geri G, Zahr N, Mariampillai K, Rosenzwajg M, Carpentier W, Musset L, Piette JC, Six A, Klatzmann D, Saadoun D, Patrice C, Costedoat-Chalumeau N.

Arthritis Res Ther. 2012 Oct 17;14(5):R221. doi: 10.1186/ar4060.

Supplemental Content

Loading ...
Support Center